SITC 2023 | Targeting myeloid cells in the future of immuno-oncology

Brent A. Hanks, MD, PhD, Duke University School of Medicine, Durham, NC, comments on recent studies intending to target myeloid cell populations in combination therapies with anti-PD-1 treatments, which are likely to be more effective than the T-cell centric strategies we have seen dominate over recent years. Dr Hanks is of the opinion that myeloid-targeting strategies will be useful in developing new immunotherapies that are likely to be more effective. This interview took place at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.